drugset / Trial / NCT00044005

Safety and Tolerability Study of Drug to Treat Schizophrenia

NCT00044005

Phase 2 Completed 98 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.

Timeline

Start
2002-09
Primary completion
2003-11
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 20 mg Oral
Subject Lurasidone Small molecule 40 mg Oral
Subject Lurasidone Small molecule 80 mg Oral

Indications